Experience

Davis Polk advised Shenzhen Hepalink Pharmaceutical Group Co., Ltd. in connection with its initial public offering and listing on the Hong Kong Stock Exchange and an international offering…

Davis Polk advised Oryzon Genomics, S.A. on its private placement of approximately 7,273,000 of its ordinary shares pursuant to a capital increase. The offering consisted of two tranches: a…

Davis Polk advised the representatives of the several underwriters in connection with the $296 million SEC-registered offering of 9,545,000 shares of common stock of 1Life Healthcare,…

Davis Polk advised the joint book-running managers and representatives of the underwriters in connection with the $69 million follow-on offering of common stock of Magenta Therapeutics…

Davis Polk advised the sole book-running manager in connection with the $215.6 million common stock offering of 6,900,000 shares of common stock of Editas Medicine, Inc. The common…

Davis Polk advised the joint book-running managers on an SEC-registered offering by Abbott Laboratories of $650 million aggregate principal amount of 1.150% notes due 2028 and $650…

Davis Polk advised the representative of the initial purchasers of a Rule 144A/Regulation S offering by Acadia Healthcare Company, Inc. of $450 million aggregate principal amount of its 5…

Davis Polk advised the representatives of the underwriters, in connection with the offering of $4.5 billion aggregate principal amount of notes issued by Merck & Co., Inc. The…

Davis Polk advised the initial purchaser in connection with a Rule 144A offering by CryoLife, Inc. of $100 million aggregate principal amount of its 4.250% convertible senior notes due 2025…

Davis Polk advised Genetron Holdings Limited on its SEC-registered initial public offering of 16,000,000 American Depositary Shares. Each ADS represents five ordinary shares. Genetron has…